Valley Brook Capital Group Inc. Has $2.47 Million Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Valley Brook Capital Group Inc. boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,660 shares of the medical research company’s stock after buying an additional 150 shares during the period. Thermo Fisher Scientific makes up about 2.1% of Valley Brook Capital Group Inc.’s investment portfolio, making the stock its 8th largest holding. Valley Brook Capital Group Inc.’s holdings in Thermo Fisher Scientific were worth $2,473,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Means Investment CO. Inc. lifted its position in Thermo Fisher Scientific by 7.5% during the third quarter. Means Investment CO. Inc. now owns 858 shares of the medical research company’s stock valued at $435,000 after purchasing an additional 60 shares during the period. KMG Fiduciary Partners LLC lifted its stake in shares of Thermo Fisher Scientific by 6.7% in the 3rd quarter. KMG Fiduciary Partners LLC now owns 3,304 shares of the medical research company’s stock worth $1,672,000 after purchasing an additional 207 shares during the period. Penobscot Wealth Management purchased a new position in shares of Thermo Fisher Scientific in the third quarter worth approximately $204,000. Concord Wealth Partners increased its holdings in Thermo Fisher Scientific by 10.0% during the third quarter. Concord Wealth Partners now owns 884 shares of the medical research company’s stock valued at $447,000 after buying an additional 80 shares during the last quarter. Finally, Everhart Financial Group Inc. boosted its stake in shares of Thermo Fisher Scientific by 5.4% during the 3rd quarter. Everhart Financial Group Inc. now owns 748 shares of the medical research company’s stock worth $379,000 after acquiring an additional 38 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Activity

In other Thermo Fisher Scientific news, Director Debora L. Spar sold 164 shares of the business’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $546.97, for a total transaction of $89,703.08. Following the sale, the director now owns 1,207 shares in the company, valued at approximately $660,192.79. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Thermo Fisher Scientific news, Director Debora L. Spar sold 164 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the completion of the sale, the director now directly owns 1,207 shares in the company, valued at approximately $660,192.79. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Michael A. Boxer sold 14,566 shares of the business’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the transaction, the senior vice president now owns 12,901 shares of the company’s stock, valued at $7,250,362. The disclosure for this sale can be found here. Insiders have sold 62,277 shares of company stock valued at $35,373,364 over the last ninety days. 0.34% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on TMO shares. Evercore ISI lifted their target price on Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a research report on Thursday, April 4th. The Goldman Sachs Group boosted their price objective on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Raymond James raised their target price on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a research note on Thursday, February 1st. Citigroup assumed coverage on shares of Thermo Fisher Scientific in a research note on Monday, March 18th. They issued a “neutral” rating and a $620.00 price objective for the company. Finally, Barclays lifted their target price on shares of Thermo Fisher Scientific from $590.00 to $615.00 and gave the company an “equal weight” rating in a research note on Thursday, April 25th. Five equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $607.35.

Thermo Fisher Scientific Trading Up 0.2 %

Shares of NYSE TMO traded up $1.13 during trading hours on Friday, reaching $572.38. The stock had a trading volume of 1,749,670 shares, compared to its average volume of 1,409,187. The firm has a market cap of $218.48 billion, a price-to-earnings ratio of 36.71, a P/E/G ratio of 2.37 and a beta of 0.80. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $603.82. The business’s fifty day moving average price is $575.39 and its two-hundred day moving average price is $533.63.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.70 by $0.41. The business had revenue of $10.35 billion for the quarter, compared to analysts’ expectations of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. Analysts expect that Thermo Fisher Scientific Inc. will post 21.64 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were paid a dividend of $0.39 per share. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. The ex-dividend date was Thursday, March 14th. Thermo Fisher Scientific’s payout ratio is presently 10.01%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.